A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Ceritinib (Primary) ; Midazolam; Warfarin
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 09 Nov 2017 Planned End Date changed from 22 Sep 2017 to 23 Nov 2017.
- 09 Nov 2017 Planned primary completion date changed from 22 Sep 2017 to 23 Nov 2017.
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.